

15<sup>th</sup> May, 2026

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Outcome of the Board Meeting**

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that Board of Directors of the Company, at its meeting held today i.e. 15<sup>th</sup> May, 2026 have considered and approved the following;

1. Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31<sup>st</sup> March, 2026. The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor's report thereon are attached herewith for your ready reference.
2. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified (i.e., unqualified) opinion on the Financial Statements (Standalone and Consolidated) for the year ended on 31<sup>st</sup> March, 2026.

The Board Meeting commenced at 16:30 hrs and concluded at **18:50** hrs

Request you to kindly take note of the same and acknowledge the receipt.

Thanking You,

Yours faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147895**



**Independent Auditor's Report on Audit of Quarterly and Annual Standalone Financial Results of Kilitch Drugs (India) Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)**

To,  
The Board of Directors of  
Kilitch Drugs (India) Limited

**Opinion**

We have audited the accompanying Statement of Standalone Audited Financial Results for the quarter/ year ended March 31, 2026 (refer 'Other Matter' section below) of **Kilitch Drugs (India) Limited** ("the Company") ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:


- i. is presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other applicable accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year ended 31 March, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, (as amended) ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.

**Management's Responsibility for the Standalone Financial Results**

The statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the accounting standards specified under section 133 of the Act, read with the relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding the assets of the Company and for preventing and detecting



frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statements, Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statements as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for purpose of expressing an opinion on the effectiveness of the Company's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence



obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our opinion is not modified in respect of this matter.

**For C Sharat & Associates**  
Chartered Accountants  
FRN : 128593W



**Chintan Sharatchandra Shah**  
Membership No. : 127551  
UDIN: 26127551PVRMXQ4522  
Place : Mumbai  
Date : 15<sup>th</sup> May, 2026



<b>KILITCH DRUGS (INDIA) LIMITED</b>						
<b>STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2026</b>						
Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701						
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com						
CIN:L24239MH1992PLC066718						
(Rs. In Lakhs except Earnings per Share data)						
		Three Months Ended			Year Ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
<b>1</b>	<b>Income</b>					
	Net Sales/ Income from operations	7,196.88	4,467.00	5,630.41	18,857.43	18,158.73
	Other Income	113.63	160.81	232.47	1,384.85	1,371.53
	<b>Total Income</b>	<b>7,310.51</b>	<b>4,627.81</b>	<b>5,862.88</b>	<b>20,242.28</b>	<b>19,530.26</b>
<b>2</b>	<b>Expenses</b>					
	Cost of Materials Consumed	2,853.23	2,532.05	2,712.76	8,780.36	9,319.06
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	146.91	(170.99)	(145.03)	106.73	(116.99)
	Employee Benefit Expenses	361.37	304.38	258.29	1,233.50	1,003.07
	Finance Cost	57.79	60.00	72.10	244.31	212.55
	Depreciation and Amortisation Expenses	70.14	56.09	51.06	228.80	173.72
	Export Product Registration/Commission	522.98	538.42	643.35	2,139.01	1,994.23
	Other Expenses	1,365.41	690.73	770.47	3,354.20	2,875.63
	<b>Total Expenses</b>	<b>5,377.83</b>	<b>4,010.68</b>	<b>4,363.00</b>	<b>16,086.91</b>	<b>15,461.27</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional items (1-2)</b>	<b>1,932.68</b>	<b>617.13</b>	<b>1,499.88</b>	<b>4,155.37</b>	<b>4,068.99</b>
<b>4</b>	Exceptional Items	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>1,932.68</b>	<b>617.13</b>	<b>1,499.88</b>	<b>4,155.37</b>	<b>4,068.99</b>
<b>6</b>	Less: Tax Expenses:-					
	Current Tax	617.90	159.79	355.86	1,085.69	985.00
	Deferred Tax	(85.12)	(31.74)	6.61	(170.28)	(31.70)
<b>7</b>	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>1,399.90</b>	<b>489.08</b>	<b>1,137.41</b>	<b>3,239.96</b>	<b>3,115.69</b>
<b>8</b>	Other Comprehensive Income (after tax)	(321.17)	151.04	(93.40)	(106.50)	(113.68)
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>1,078.73</b>	<b>640.12</b>	<b>1,044.01</b>	<b>3,133.46</b>	<b>3,002.01</b>
<b>10</b>	Paid-Up equity share capital (Face Value Rs 10 per share)	<b>3,496.16</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>3,496.16</b>	<b>1,608.23</b>
<b>11</b>	Other Equity				<b>29,804.51</b>	<b>23,686.14</b>
<b>12</b>	<b>Earning per share (not annualised)</b>					
	(a) Basic	4.08	1.37	7.07	9.57	19.37
	(b) Diluted	4.08	1.37	7.07	9.57	19.37

**Notes:**

- The above audited Standalone Financial Results of the Company for the quarter and year ended 31st March, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th May, 2026.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter ended 31st March, 2026, the Company issued 1,74,80,782 fully paid up Equity Shares of face value ₹ 10 each to its existing shareholders in the ratio of 1:1 i.e. 1 fully paid up bonus equity share issued for every 1 fully paid up equity share held by the eligible equity shareholders of the company as on the record date fixed by the company for this purpose. The Bonus equity shares were allotted on 25th March, 2026.
- The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and 31st March, 2025 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable with the current periods.



Place : Mumbai  
Dated: 15th May, 2026

For and on behalf of the Board of Directors

Mukund Mehta  
Managing Director  
DIN:- 00147876



**KILITCH DRUGS (INDIA) LIMITED**

AUDITED STANDALONE BALANCE SHEET AS AT 31ST MARCH 2026

CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
<b>ASSETS</b>		
<b>Non-current assets</b>		
- Property, Plant and Equipment	1,927.12	1,915.75
- Capital work-in-progress	14,001.93	4,729.45
- Other Intangible Assets	26.41	35.14
<b>Financial assets</b>		
- Investments	7,189.06	7,185.10
- Loans/Advances	5,728.20	5,423.15
- Other Financial Assets	0.50	1.81
Deferred tax assets (Net)	457.93	287.64
<b>(A)</b>	<b>29,331.15</b>	<b>19,578.03</b>
<b>Current Assets</b>		
- Inventories	1,152.07	1,530.96
<b>Financial assets</b>		
- Investments	5,196.33	4,951.77
- Trade Receivables	11,724.43	8,339.83
- Cash & Cash Equivalents	929.63	740.85
- Other Bank Balances	100.20	4.73
- Other Financial Assets	3.25	3.20
Other Current Assets	1,508.48	666.42
<b>(B)</b>	<b>20,614.39</b>	<b>16,237.76</b>
<b>TOTAL ASSETS (A + B)</b>	<b>49,945.54</b>	<b>35,815.79</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
- Equity Share Capital	3,496.16	1,608.23
- Other Equity	29,804.51	23,686.14
<b>(A)</b>	<b>33,300.67</b>	<b>25,294.37</b>
<b>Liabilities</b>		
<b>Non-Current liabilities</b>		
<b>Financial Liabilities</b>		
- Borrowings	5,860.35	2,777.04
Provisions	67.94	24.53
<b>(B)</b>	<b>5,928.29</b>	<b>2,801.57</b>
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
- Borrowings	2,977.62	2,132.43
- Trade Payables		
Micro and Small Enterprises	-	-
Others	6,819.42	4,742.22
- Other Financial Liabilities	4.50	7.03
Provisions	221.87	143.79
Current Tax Liabilities [Net]	656.59	668.55
Other Current Liabilities	36.59	25.84
<b>(C)</b>	<b>10,716.59</b>	<b>7,719.85</b>
<b>TOTAL EQUITY AND LIABILITIES (A+B+C)</b>	<b>49,945.54</b>	<b>35,815.79</b>




Place : Mumbai  
Dated: 15th May, 2026

For and on behalf of the Board of Directors

Mukund Mehta  
Managing Director

DIN:- 00147876



**KILITCH DRUGS (INDIA) LIMITED**  
**AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2026**  
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Particulars	Year Ended 31st March, 2026		Year Ended 31st March 2025	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		4,155.37		4,068.99
<i>Adjustments for:</i>				
Depreciation and amortization	228.80		173.72	
Interest income	(312.25)		(358.74)	
Dividend income	(3.47)		(0.55)	
(Profit)/Loss on sale of Investments	(362.25)		(652.17)	
Sundry Balances written back	8.20		-	
Provision for Gratuity & Leave Encashment	68.09		0.44	
Interest Expenses	244.31		212.55	
Expected Credit Loss	344.72		115.96	
(Profit) / Loss from Investment in Partnership Firm	(0.56)		0.04	
Net unrealised exchange (gain) / loss	(127.00)	88.59	(59.99)	(568.75)
<b>Operating profit / (loss) before working capital changes</b>		<b>4,243.96</b>		<b>3,500.24</b>
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories	378.89		(1,132.16)	
Trade receivables	(3,610.52)		(2,215.35)	
Other current assets	(842.06)		94.07	
Deposits & advances	(40.57)		(29.51)	
Other financial assets	(0.05)		0.17	
<i>Operating Liabilities:</i>				
Trade payables	2,077.20		2,126.09	
Other current liabilities	8.23		4.45	
Provisions	70.98	(1,957.90)	22.22	(1,130.01)
<b>Gross cash flow from / (used in) operating activities</b>		<b>2,286.06</b>		<b>2,370.23</b>
Direct Taxes (Paid) /refunded		(1,054.05)		(846.95)
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>1,232.01</b>		<b>1,523.28</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Purchases of Property, Plant & Equipment and CWIP	(9,503.92)		(4,687.34)	
Loans/Advances to related Parties	(264.48)		(346.69)	
Proceeds/(Purchases) (Net) of Current Investments	(50.00)		527.33	
Proceeds/(Purchases) (Net) of Non-Current Investments	(3.40)		(57.87)	
Movement in other Bank balances	(94.16)		62.79	
Interest received	312.20		358.74	
Dividend received	3.47		0.55	
		(9,600.29)		(4,142.49)
		(9,600.29)		(4,142.49)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(9,600.29)</b>		<b>(4,142.49)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds From Right Issue of Equity Share Capital ( incl. Share Premium-net of share issue expenses)	4,872.82		-	
Proceeds from Borrowings (Net of Repayments)	3,928.50		1,777.74	
Interest paid	(244.31)		(212.55)	
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>8,557.02</b>		<b>1,565.19</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>188.75</b>		<b>(1,054.03)</b>
Cash and cash equivalents at the beginning		740.86		1,794.88
<b>Cash and cash equivalents at the end</b>		<b>929.61</b>		<b>740.85</b>
<b>Cash and cash equivalents at the end *</b>				
* Comprises:				
(a) Cash on hand		2.74		3.58
(b) Balances with banks				
(i) In current accounts		925.33		733.45
(ii) In earmarked accounts		1.56		3.82
		<b>929.61</b>		<b>740.85</b>




Place : Mumbai  
Dated: 15th May, 2026

For and on behalf of the Board of Directors

Mukund Mehta  
Managing Director

DIN:-00147876



**Independent Auditor's Report on Audit of Quarterly and Annual Consolidated Financial Results of Kilitch Drugs (India) Limited ("the Parent") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)**

To,  
**The Board of Directors of  
Kilitch Drugs (India) Limited,**

**Opinion**

We have audited the accompanying Statement of "Audited Consolidated Financial Results for the Quarter/Year ended March 31, 2026" (refer paragraph 3 of 'Other Matters' section below) of **Kilitch Drugs (India) Limited** ('the Parent') which includes its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive income/loss of its associates for the quarter and year ended March 31, 202 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the audit reports of the other auditors on standalone financial statements/financial results/financial information of the subsidiaries, referred in Other Matters section below.

The statement:

- i. includes the results of entities as given below:

**List of Subsidiaries:**

1. Monarchy Healthserve Private Limited
  2. Kilitch Estro Biotech PLC – Foreign Subsidiary
- ii. is presented in accordance with requirements of Regulations 33 of Listing Regulations
  - iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the quarter and year then ended.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (as amended) (the "Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group, its associates in accordance with the "Code of Ethics" issued by the Institute of Chartered Accountants of India together with the



ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Responsibilities of the Management and the Board of Directors for the Statement**

This Statement is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Statement has been compiled from the related audited consolidated interim financial information for the quarter and year ended 31 March, 2026. This responsibility includes the preparation and presentation of the Statement that give a true and fair view of the consolidated net profit and consolidated other comprehensive loss and other financial information of the Group including its associates in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.


The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group and of its associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is also responsible for overseeing the financial reporting process to the Group.

### **Auditor's Responsibility for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Board of Directors.
- Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and of its associates to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statements, including the disclosures, and whether the statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated 29th March, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial information/financial results of the entities within the Group and its associates, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated 29th March, 2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable

### Other Matters

1. The accompanying Statement includes the audited financial results/statements and other financial information, in respect of:

One subsidiary, whose financial results/statements reflect total assets of Rs. 1,772.77 lakhs as at March 31, 2026, total revenues of Rs. Nil and Rs Nil, total Net Profit/(Loss) after tax of Rs. (22.01) lakhs and Rs. (88.09) lakhs, total comprehensive loss of Rs. (22.01) lakhs and Rs. (88.09) lakhs, for the quarter and the year ended on that date respectively, and net cash outflows of Rs. 0.01 lakhs for the year ended March 31, 2026 as considered in the Statement which have been audited by their respective independent auditors.

The independent auditor's report on the financial statements of the entity have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of such auditor and the procedures performed by us as stated in paragraph above.

2. The accompanying Statement includes unaudited financial results /statements and other unaudited financial information in respect of:

One foreign subsidiary, whose financial results/statements reflect total assets of Rs. 6,098.62 lakhs as at March 31, 2026, total revenues of Rs. 1,765.87 and Rs. 4,756.58 lakhs, total Net Profit/(Loss) after tax of Rs. 110.38 lakhs and Rs (201.84) lakhs, total comprehensive loss of Rs. 110.38 lakhs and Rs. (201.84) lakhs, for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 408.58 lakhs for the year ended March 31, 2026 as considered in the Statement which have been audited by their respective independent auditors.

These unaudited financial statements / financial results have been approved and furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on such unaudited financial statements/ financial results.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors in Para 1 and the unaudited Financial Results/ Financial Statements certified by the Management referred in Para 2 above.



3. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Statement is not modified in respect of this matter.

**For C Sharat & Associates**  
Chartered Accountants  
FRN: 128593W



**Chintan Sharatchandra Shah**  
Membership No.: 127551  
UDIN: 26127551RDEIXR4294  
Place : Mumbai  
Date :15<sup>th</sup> May, 2026

**KILITCH DRUGS (INDIA) LIMITED**  
**CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31ST MARCH, 2026**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718


(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED				
		Three Months Ended			Year Ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
	Audited	Unaudited	Audited	Audited	Audited	
1	<b>Income</b>					
	Net Sales/Income from Operations	8,960.27	5,380.80	6,122.58	23,547.49	19,831.85
	Other Income	49.27	152.81	169.75	1,123.86	1,116.06
	<b>Total Income</b>	<b>9,009.54</b>	<b>5,533.61</b>	<b>6,292.33</b>	<b>24,671.35</b>	<b>20,947.91</b>
2	<b>Expenses</b>					
	Cost of Materials Consumed	4,268.56	3,259.75	3,014.73	12,506.59	10,574.97
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	146.91	(170.99)	(145.02)	106.73	(116.99)
	Employee Benefit Expenses	428.71	350.84	288.06	1,430.58	1,132.38
	Finance Cost	144.44	114.69	160.13	556.08	504.13
	Depreciation and Amortisation Expenses	98.05	93.66	84.67	362.31	311.02
	Export Product Registration/Commission	523.59	538.61	643.47	2,140.24	1,995.02
	Other expenses	1,378.23	787.44	861.91	3,703.38	3,099.96
	<b>Total Expenses</b>	<b>6,988.49</b>	<b>4,974.00</b>	<b>4,907.95</b>	<b>20,805.91</b>	<b>17,500.49</b>
3	<b>Profit before Exceptional items (1-2)</b>	<b>2,021.05</b>	<b>559.61</b>	<b>1,384.38</b>	<b>3,865.44</b>	<b>3,447.42</b>
4	Exceptional Items	-	-	-	-	-
5	<b>Profit from ordinary activities before tax (3+4)</b>	<b>2,021.05</b>	<b>559.61</b>	<b>1,384.38</b>	<b>3,865.44</b>	<b>3,447.42</b>
6	Less : Tax Expenses					
	Current Income Tax	617.90	159.79	355.86	1,085.69	985.00
	Deferred Tax	(85.13)	(31.72)	6.66	(170.28)	(31.59)
7	<b>Profit after tax for the period from continuing operations (5-6)</b>	<b>1,488.28</b>	<b>431.54</b>	<b>1,021.86</b>	<b>2,950.03</b>	<b>2,494.01</b>
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	1,488.28	431.54	1,021.86	2,950.03	2,494.01
9	Other Comprehensive Income (after Tax)	(321.17)	151.03	(93.40)	(106.50)	(113.68)
10	<b>Total Comprehensive Income (after taxes) (8+9)</b>	<b>1,167.11</b>	<b>582.57</b>	<b>928.46</b>	<b>2,843.53</b>	<b>2,380.33</b>
11	<b>Net Profit / (Loss) attributable to</b>					
	a) Owner of the Company	1,451.85	443.22	1,039.94	3,016.64	2,670.06
	b) Non Controlling interest	36.43	(11.68)	(18.08)	(66.61)	(176.05)
12	<b>Other Comprehensive Income attributable to</b>					
	a) Owner of the Company	(321.17)	151.03	(93.40)	(106.50)	(113.68)
	b) Non Controlling interest	-	-	-	-	-
13	<b>Total Income attributable to</b>					
	a) Owner of the Company	1,130.68	594.25	946.54	2,910.14	2,556.38
	b) Non Controlling interest	36.43	(11.68)	(18.08)	(66.61)	(176.05)
14	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	<b>3,496.16</b>	<b>1,748.08</b>	<b>1,608.23</b>	<b>3,496.16</b>	<b>1,608.23</b>
15	<b>Other Equity</b>				<b>24,469.17</b>	<b>18,624.68</b>
16	<b>Earning per share (not annualised)</b>					
	(a) Basic	4.24	1.25	6.47	8.91	16.60
	(b) Diluted	4.24	1.25	6.47	8.91	16.60

**Notes:**

- The above audited Consolidated Financial Results of the Company for the quarter/year ended 31st March, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 15th May, 2026.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- During the quarter ended 31st March, 2026, the Company issued 1,74,80,782 fully paid up Equity Shares of face value ₹ 10 each to its existing shareholders in the ratio of 1:1 i.e. 1 fully paid up bonus equity share issued for every 1 fully paid up equity share held by the eligible equity shareholders of the company as on the record date fixed by the company for this purpose. The Bonus equity shares were allotted on 25th March, 2026.
- The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and 31st March, 2025 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
- The figures for the corresponding previous periods have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board of Directors  
  
**Mukund P. Mehta**  
 Director  
 DIN:- 00147876



Place: Mumbai  
 Date: 15th May, 2026


<b>KILITCH DRUGS (INDIA) LIMITED</b>		
AUDITED CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2026		
CIN:L24239MH1992PLC066718		
(Rs. In Lakhs)		
Particulars	As at 31st March, 2026	As at 31st March, 2025
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and Equipment	4,869.58	4,552.43
Capital work-in-progress	14,001.93	4,729.45
Other Intangible assets	26.41	35.14
Goodwill on Merger	1,769.34	1,853.60
<b>Financial assets</b>		
- Investments	2,288.15	2,284.19
- Loans/Advances	141.29	142.19
- Other Financials Assets	0.50	1.81
Deferred tax assets (Net)	458.21	287.92
<b>(A)</b>	<b>23,555.41</b>	<b>13,886.73</b>
<b>Current assets</b>		
Inventories	1,152.07	1,530.96
<b>Financial assets</b>		
- Investments	5,196.33	4,951.77
- Trade and other receivables	12,017.71	8,473.88
- Cash and cash equivalents	1,577.40	980.05
- Other Bank Balances	100.20	4.73
- Other Financials Assets	3.25	3.20
Other current assets	2,172.55	1,447.06
<b>(B)</b>	<b>22,219.51</b>	<b>17,391.65</b>
<b>TOTAL ASSETS (A + B)</b>	<b>45,774.92</b>	<b>31,278.38</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	3,496.16	1,608.23
Other Equity	24,469.17	18,624.68
<b>Equity attributable to the owners</b>	<b>27,965.33</b>	<b>20,232.91</b>
Non-controlling interest	(278.62)	(187.11)
<b>(A)</b>	<b>27,686.71</b>	<b>20,045.80</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
- Borrowings	5,860.35	2,777.04
Provisions	67.94	24.53
<b>(B)</b>	<b>5,928.29</b>	<b>2,801.57</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
- Borrowings	3,010.55	2,165.36
- Trade Payables		
Micro and Small Enterprises		
Others	7,964.65	5,415.74
- Other financial liabilities	4.50	7.03
Provisions	222.23	148.48
Current tax Liabilities (Net)	656.59	668.55
Other current liabilities	301.40	25.85
<b>(C)</b>	<b>12,159.92</b>	<b>8,431.01</b>
<b>TOTAL EQUITY AND LIABILITIES (A + B + C)</b>	<b>45,774.92</b>	<b>31,278.38</b>

Place : Mumbai  
Date : 15th May, 2026



For and on behalf of the Board of Directors


Mukund P. Mehta  
Managing Director  
DIN:- 00147876



**KILITCH DRUGS (INDIA) LIMITED**  
**AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2026**  
CIN:L24239MH1992PLC066718

(Rs. In Lakhs)

Particulars	For the Year ended 31st March 2026		For the Year ended 31st March 2025	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		3,865.44		3,447.43
<u>Adjustments for:</u>				
Depreciation and amortisation	362.31		311.02	
Interest income	(51.21)		(102.56)	
Dividend income	(3.47)		(0.55)	
(Profit)/Loss on sale of Investments	(362.25)		(652.17)	
Share of (Profit)/ Loss from Partnership Firm	(0.56)		0.04	
Sundry Balances written back	8.20		-	
Provision for Gratuity & Leave Encashment	68.09		0.44	
Interest Expenses	556.08		504.13	
Expected Credit Loss	344.72		115.96	
Net unrealised exchange (gain) / loss	(127.00)	794.91	(59.99)	116.32
<b>Operating profit / (loss) before working capital changes</b>		<b>4,660.35</b>		<b>3,563.76</b>
<u>Changes in working capital:</u>				
<u>Operating Assets:</u>				
Inventories	378.89		(1,132.16)	
Trade receivables	(3,753.35)		(2,207.48)	
Other financial Assets	(0.05)		-	
Other current assets	(725.50)		(432.07)	
Deposit & Advances	0.89		(70.67)	
<u>Operating Liabilities:</u>				
Trade payables	2,548.91		2,856.85	
Other financial liabilities	(2.53)		(0.77)	
Other current liabilities	275.55		5.23	
Short-term provisions	66.65	(1,210.54)	18.49	(962.58)
Gross cash flow from / (used in) operating activities		3,449.81		2,601.18
Direct Taxes (Paid) / refunded		(1,054.05)		(846.95)
<b>Net cash flow from / (used in) operating activities</b>		<b>2,395.76</b>		<b>1,754.23</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Capital expenditure on PPE,CWIP including capital advances	(9,950.74)		(4,687.34)	
Proceeds (Net) from the sale of Current investments	(50.00)		527.33	
(Purchase)/Sale (Net) of long-term investments:	(3.40)		(0.75)	
Movement in other Bank balance	(94.16)		62.79	
Interest received	51.16		102.73	
Dividend received	3.47		0.55	
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(10,043.67)</b>		<b>(3,994.69)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds From Right Issue of Equity Share Capital ( incl. Share Premium- net of share issue expenses)	4,872.82		-	
Proceeds from Borrowings (Net of Repayments)	3,928.51		1,777.75	
Proceeds from Minorities	-		50.71	
Interest paid	(556.08)		(504.13)	
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>8,245.25</b>		<b>1,324.33</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>597.34</b>		<b>(916.13)</b>
Cash and cash equivalents at the beginning of the year		980.06		1,896.18
<b>Cash and cash equivalents at the end of the year</b>		<b>1,577.40</b>		<b>980.05</b>
<b>Cash and cash equivalents at the end of the year *</b>				
* Comprises:				
(a) Cash on hand		2.74		3.58
(b) Balances with banks				
(i) In current accounts		1,573.10		972.65
(ii) In earmarked accounts		1.56		3.82
		<b>1,577.40</b>		<b>980.05</b>



Place : Mumbai  
Date : 15th May, 2026

For and on behalf of the Board of Directors

Mukund P. Mehta  
Managing Director  
DIN:- 00147876

